Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Net Cash Flow (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Net Cash Flow for 15 consecutive years, with -$979017.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Cash Flow fell 28.34% year-over-year to -$979017.0, compared with a TTM value of -$882864.0 through Sep 2025, up 10.33%, and an annual FY2024 reading of -$306141.0, up 63.09% over the prior year.
  • Net Cash Flow was -$979017.0 for Q3 2025 at BioRestorative Therapies, down from $326462.0 in the prior quarter.
  • Across five years, Net Cash Flow topped out at $19.9 million in Q4 2021 and bottomed at -$11.4 million in Q3 2022.
  • Average Net Cash Flow over 5 years is -$149424.9, with a median of -$629364.0 recorded in 2021.
  • Peak annual rise in Net Cash Flow hit 589.87% in 2021, while the deepest fall reached 18190.53% in 2021.
  • Year by year, Net Cash Flow stood at $19.9 million in 2021, then crashed by 124.38% to -$4.9 million in 2022, then surged by 67.29% to -$1.6 million in 2023, then surged by 42.68% to -$911208.0 in 2024, then decreased by 7.44% to -$979017.0 in 2025.
  • Business Quant data shows Net Cash Flow for BRTX at -$979017.0 in Q3 2025, $326462.0 in Q2 2025, and $680899.0 in Q1 2025.